Silmitasertib sodium salt

SKU: orb1308420

Description

Silmitasertib sodium salt

Research Area

Cell Biology, Metabolism Research, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1309357-15-0
• MW: 371.75
• Purity: 99.62%
• Formula: C₁₉H₁₁ClN₃NaO₂
• SMILES: [Na+].[O-]C(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21
• Target: Autophagy,Casein Kinase
• Solubility: H2O:12.5 mg/mL (33.62 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (10.76 mM);DMSO:38.33 mg/mL (103.11 mM)

Bioactivity

• Target IC50:
  CK2α:1 nM|CK2α:1 nM
• In Vivo:
  Silmitasertib (CX-4945), administered at doses of 25 or 75 mg/kg orally, was well tolerated and demonstrated strong antitumor effects alongside significant decreases in the mechanistic biomarker phospho-p21 (T145) in murine xenograft model.
• In Vitro:
  Silmitasertib induces cytotoxicity and apoptosis, and exerts anti Proliferative effects in hematological tumors by downregulating CK2 expression and suppressing activation of CK2-mediated PI3K/Akt/mTOR signaling pathway. Silmitasertib (CX-4945) resultes in cell-cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells, attenuates PI3K/Akt signalin an the ant Proliferative activity of Silmitasertib is correlated with expression levels o the CK2α catalytic subunit, attenuation of PI3K/Akt signalin. Silmitasertib with PS-341 treatment prevents leukemic cells from engaging a functional UPR in order to buffe the PS-341-mediated proteotoxic stress in ER lumen, and decreases pro-survival ER chaperon BIP/Grp78 expressio.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

CK2α, CK2α', CK2, CX 4945, CX4945, CX-4945, CX-4945 sodium, CX-4945 sodium salt, CaseinKinase, Casein Kinase, Autophagy, Inhibitor, inhibit, Silmitasertib, Silmitasertib sodium, Silmitasertib sodium salt

Compound Identifiers

PubChem CID

49788959